| T900607 / Amgen |
NCT00043459: Study of T900607-Sodium in Previously Treated Patients With Non-Hodgkin's Lymphoma. |
|
|
| Terminated | 2 | 35 | US | intravenous T900607-sodium | Tularik | Non-Hodgkin's Lymphoma | | 03/03 | | |
NCT00054262: T900607 in Treating Patients With Unresectable Liver Cancer |
|
|
| Completed | 2 | | US | T900607 | University Hospitals Seidman Cancer Center, National Cancer Institute (NCI) | Liver Cancer | 03/04 | 09/10 | | |
NCT00054249: T900607 in Treating Patients With Gastroesophageal Junction Cancer |
|
|
| Completed | 2 | | US | T900607 | University Hospitals Seidman Cancer Center, National Cancer Institute (NCI) | Gastric Cancer | 10/04 | 09/10 | | |
NCT00043433: Study of T900607-Sodium in Chemotherapy Naive Patients With Hepatocellular Carcinoma. |
|
|
| Unknown status | 2 | 35 | US, RoW | intravenous T900607-sodium | Tularik | Hepatocellular Carcinoma | | | | |
NCT00043446: Study of T900607-Sodium in Previously Treated Patients With Ovarian Cancer. |
|
|
| Unknown status | 2 | 35 | US | intravenous T900607-sodium | Tularik | Ovarian Neoplasms | | | | |
NCT00048529: Study of T900607-Sodium in Subjects With Previously Treated Gastric Cancer or Adenocarcinoma of the Esophagus |
|
|
| Suspended | 2 | 70 | US | T900607-sodium intravenous | Tularik | Gastric Cancer, Esophageal Neoplasms | | | | |
